Cornerstone Planning LLC Buys New Stake in AbbVie Inc. $ABBV

Cornerstone Planning LLC bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 14,972 shares of the company’s stock, valued at approximately $3,421,000.

Several other hedge funds also recently bought and sold shares of ABBV. Rockefeller Capital Management L.P. raised its holdings in shares of AbbVie by 10.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 883,644 shares of the company’s stock worth $201,904,000 after acquiring an additional 81,375 shares during the last quarter. Osbon Capital Management LLC acquired a new stake in shares of AbbVie during the fourth quarter valued at $74,000. Lane Brothers & Co. Inc. purchased a new stake in AbbVie during the 4th quarter worth about $367,000. Fund Advisors of America Inc FL purchased a new stake in AbbVie during the 4th quarter worth about $897,000. Finally, World Investment Advisors raised its stake in AbbVie by 12.0% in the 4th quarter. World Investment Advisors now owns 127,623 shares of the company’s stock valued at $29,161,000 after purchasing an additional 13,698 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ABBV. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a report on Thursday, April 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Royal Bank Of Canada began coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price on the stock. Finally, Piper Sandler lifted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Price Performance

Shares of ABBV stock opened at $216.63 on Friday. The firm’s 50-day simple moving average is $212.18 and its 200-day simple moving average is $218.76. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The firm has a market cap of $382.74 billion, a P/E ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.46 earnings per share. Analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.